Browsing Category
Pharma Industry News
4739 posts
Business-News-Today.com section for global pharma industry news, Indian pharma sector latest news, pharma sector news today, pharmaceuticals industry news.
Clearmind Medicine files U.S. patent for non-hallucinogenic MEAI therapy targeting cocaine addiction
Find out how Clearmind Medicine’s new U.S. patent filing for its non-hallucinogenic MEAI therapy could transform cocaine addiction treatment and investor sentiment.
Can Mycenax’s ADC linker license deal with RIN boost Taiwan’s global CDMO standing?
Find out how Mycenax Biotech Inc. is reshaping Taiwan’s ADC CDMO positioning through a global linker technology license deal with Japan’s RIN Institute.
FDA approves GSK’s Blenrep for myeloma—what sets it apart from CAR-T options?
GSK’s Blenrep approved by the FDA for relapsed multiple myeloma after Phase III trial success. Learn what this means for U.S. patients and global expansion.
Could MediciNova’s MN-002 redefine how atherosclerosis is treated? Peer-reviewed study says yes
Learn how MediciNova’s MN-002 boosts macrophage cholesterol efflux and why scientists say it could transform atherosclerosis treatment.
Can Moleculin’s MIRACLE trial redefine AML treatment? Company to showcase study at leukemia event
Find out how Moleculin’s MIRACLE phase 3 trial could reshape AML treatment as the company presents its latest progress at the Madrid leukemia meeting.
Pfizer thought it secured Metsera—then Novo Nordisk crashed the party with a bigger bid
Novo Nordisk just challenged Pfizer’s Metsera deal with a $9B rival bid. Find out how this could reshape the weight-loss drug landscape in 2025.
N2OFF enters cancer-drug discovery market through MitoCareX merger
Find out how N2OFF’s merger with MitoCareX is reshaping its business and targeting pancreatic & lung cancers!
Lantern Pharma highlights AI-powered cancer research platforms during UNT’s first AI for Biology & Medicine symposium
Find out how Lantern Pharma is redefining AI-driven cancer drug development with predictBBB.ai and LBx-AI at UNT’s inaugural AI4BM symposium.
Can Merck sustain its oncology-led momentum? Keytruda, WINREVAIR, and pipeline drive Q3 beat
Merck’s Q3 2025 results beat expectations on Keytruda strength and a rising pipeline. Explore what’s driving EPS upgrades and future growth bets.
Breakthrough results: Intensity Therapeutics’ INT230-6 delivers strong survival and immune response in phase 1/2 cancer trial
Find out how Intensity Therapeutics’ INT230-6 achieved 11.9-month survival and immune activation in metastatic cancer—read what this means for biotech investors.